The Digital Health Podcast with Fexingo: Wearables, Diagnostics, and Health Software

In this episode of The Digital Health Podcast, Lucas and Luna explore the emerging world of wearable microneedle patches that deliver drugs through the skin without pain. They focus on the specific case of Zosano Pharma's transdermal patch for migraine, which failed in clinical trials in 2021, and contrast it with newer players like Vaxxas and LTS Lohmann that are targeting vaccines and insulin. Lucas breaks down the key engineering challenge: how to make microneedles long enough to penetrate the stratum corneum but short enough to avoid pain receptors. Luna asks whether the FDA's regulatory pathway for combination products is slowing adoption. The hosts also discuss the potential market size: Grand View Research estimates the transdermal drug delivery market could reach $12.3 billion by 2027. They debate whether the biggest win will be in chronic disease management (insulin, GLP-1 agonists) or mass vaccination campaigns. The episode ties the conversation to listener support, noting that independent digital health journalism helps separate real innovation from hype. A focused, technical conversation for anyone interested in how wearables are moving beyond sensors into therapeutics.

#DigitalHealth #WearableTech #MicroneedlePatches #DrugDelivery #Transdermal #ZosanoPharma #Vaxxas #LTSLohmann #Migraine #Insulin #GLP1 #FDA #CombinationProducts #Business #Technology #FexingoBusiness #BusinessPodcast #HealthTech

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how a handful of digital health startups are rethinking the primary care visit from the ground up. The episode focuses on 'ambient listening' AI — software that listens to the patient-clinician conversation and automatically generates clinical notes, diagnoses, and billing codes in real time. They examine the specific case of Abridge, which recently partnered with several major health systems, and discuss the numbers: how much time physicians actually spend on documentation (around 15 minutes per appointment after hours), and how ambient listening aims to cut that to zero. They also touch on the tricky regulatory question — when an AI listens in, who owns the transcript? And what happens when the model makes a clinical error in its note? The hosts treat the topic with a sharp business lens, comparing the unit economics of ambient listening to traditional medical scribes (human scribes cost roughly $15 to $20 per hour; AI scribes are targeting $1 to $2 per visit). The episode closes with a forward-looking question: if the listening is automated, and the note-taking is automated, what part of the doctor-patient relationship becomes the truly human middle?

#AmbientListening #AIinHealthcare #PrimaryCare #DigitalHealth #Abridge #MedicalScribes #ClinicianBurnout #HealthTech #Business #FexingoBusiness #BusinessPodcast #DoctorPatient #EHR #Documentation #HealthAI #Startup #Podcast #Technology

Keep every episode free: buymeacoffee.com/fexingo

In episode 35 of The Digital Health Podcast, Lucas and Luna unpack the FDA's evolving framework for regulating software-as-a-medical-device (SaMD). They focus on the agency's 2025 guidance on AI/ML-enabled devices and how it affects startups like IDx and Caption Health. Lucas explains the 'predetermined change control plan'—a mechanism that lets algorithms update without full re-clearance. Luna questions whether this really accelerates innovation or just shifts risk. They also discuss the de novo pathway, the 510(k) exemption for low-risk tools, and why some digital health companies are choosing not to pursue FDA clearance at all. A concrete look at regulatory strategy for anyone building or investing in health software.

#DigitalHealth #SaMD #FDA #SoftwareAsAMedicalDevice #AIinHealthcare #MedTech #RegulatoryStrategy #IDx #CaptionHealth #PredeterminedChangeControlPlan #510kClearance #DeNovoPathway #Business #Technology #HealthTech #FexingoBusiness #BusinessPodcast #DigitalTherapeutics

Keep every episode free: buymeacoffee.com/fexingo

Remote patient monitoring has moved beyond chronic disease management into mainstream primary care. Lucas and Luna examine a specific case: a midsize clinic network in Ohio that deployed cellular-connected blood pressure cuffs and pulse oximeters for 2,000 patients with hypertension. They discuss the early results — a 14 percent reduction in systolic blood pressure over six months — and the operational challenges of integrating device data into electronic health records. The conversation also covers the financial incentives: Medicare's RPM billing codes now reimburse roughly $110 per patient per month, making the model viable for independent practices. But questions remain about equity, data burden, and whether RPM widens or closes the care gap. A grounded look at what's actually working in remote monitoring today, with real numbers and real trade-offs.

#RemotePatientMonitoring #PrimaryCare #Hypertension #RPM #Medicare #DigitalHealth #HealthTech #Wearables #BloodPressure #PulseOximetry #EHR #ClinicalOutcomes #HealthcareCosts #HealthEquity #Business #Technology #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

Episode 33 of The Digital Health Podcast with Fexingo explores how artificial intelligence is analyzing retinal scans to detect signs of diabetic retinopathy, cardiovascular disease, and even Alzheimer's risk years before symptoms appear. Lucas and Luna zero in on the FDA-cleared system from IDx-DR (now LumineticsCore) and the new wave of deep learning models trained on millions of fundus photographs. They discuss the clinical validation data from a 2024 JAMA study, the workflow integration challenges in primary care offices, and why reimbursement codes are the bottleneck for scaling. No hype, just the real metrics: sensitivity above 87% in real-world deployment and the false-positive tradeoffs that keep regulators cautious. If you're following where computer vision meets clinical workflow, this is the episode that cuts through the noise.

#AI #RetinalImaging #DiabeticRetinopathy #IDxDR #LumineticsCore #ComputerVision #DeepLearning #FDACleared #JAMA #Screening #PrimaryCare #Ophthalmology #DigitalHealth #HealthTech #Diagnostics #BusinessAndTechnology #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore how wearables like the Oura Ring and Apple Watch can detect early signs of viral infections before symptoms appear. They discuss the 2020 study from Stanford that showed temperature changes and heart rate variability shifts preceding COVID-19 symptoms by 2-3 days, and how companies like Fitbit are now building disease-detection algorithms. The hosts drill into the specific physiological signals — resting heart rate, skin temperature, respiratory rate — and why the FDA is treating these as a new class of pre-symptomatic screening tools. They also examine the privacy trade-offs: who owns the infection data? Do employers get access? And what happens when a wearable flags an infection that doesn't exist? The episode unpacks the technology, the regulatory landscape, and the ethical questions that come with turning a consumer gadget into a public health sensor.

#Wearables #EarlyInfectionDetection #OuraRing #AppleWatch #Fitbit #FDA #HealthTech #DigitalHealth #Biometrics #HeartRateVariability #SkinTemperature #MachineLearning #Privacy #StanfordStudy #COVID19 #Business #Technology #FexingoBusiness

Keep every episode free: buymeacoffee.com/fexingo

Episode 31 of The Digital Health Podcast explores how Oura Ring pivoted from a niche sleep tracker to a corporate wellness platform used by employers like Cisco and Bank of America. Lucas and Luna break down the numbers: Oura's reported 600,000 unit sales by mid-2025, the shift from direct-to-consumer to B2B contracts, and how its FDA-cleared blood oxygen and heart rate sensors crossed the line from gadget to legitimate health tool. They discuss the tension between privacy and data pooling in workplace wellness, and what Oura's success means for the broader wearables market. No fluff, just the strategy behind the Ring's quiet takeover of corporate health programs.

#OuraRing #Wearables #EmployerHealth #CorporateWellness #DigitalHealth #BusinessStrategy #HealthTech #SleepTracking #FDA #Cisco #BankOfAmerica #B2B #Privacy #WearableTech #FexingoBusiness #BusinessPodcast #HealthInnovation #LucasAndLuna

Keep every episode free: buymeacoffee.com/fexingo

Episode 30 of The Digital Health Podcast with Fexingo dives into how Dexcom turned continuous glucose monitoring from a niche diabetes tool into a mainstream wellness product. Lucas and Luna break down the key strategic moves Dexcom made to pull ahead of Abbott's FreeStyle Libre: the G7 sensor's smaller design, the decision to go direct-to-consumer with over-the-counter sales, and the controversial move to launch 'Dexcom Stelo' for non-diabetic health optimizers. They discuss the market numbers—Dexcom's 38% revenue growth in 2025 versus Abbott's 12% in diabetes care—and what the FDA's loosening of prescription requirements means for the future of wearable diagnostics. If you're in digital health or just watching where the smartwatch replacement cycle goes, this episode gives you the specific competitive dynamics shaping the CGM duopoly.

#Dexcom #CGM #ContinuousGlucoseMonitor #AbbottFreeStyleLibre #DiabetesTech #DigitalHealth #Wearables #HealthTech #FDA #OverTheCounter #DexcomStelo #GlucoseMonitoring #WellnessTech #Business #Technology #FexingoBusiness #BusinessPodcast #HealthInnovation

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna explore the explosive growth of continuous glucose monitors beyond diabetes management. Lucas explains how Abbott's Freestyle Libre and Dexcom's G7 are now being marketed to 'health optimizers' and athletes. He breaks down the key numbers: the total addressable market expanding from 30 million diabetics to 400 million pre-diabetics plus millions of wellness consumers. Luna questions the evidence base — does real-time glucose data actually improve outcomes in non-diabetics? Lucas cites early studies from Levels and NutriSense showing behavioral changes but acknowledges the 'data for data's sake' criticism. They discuss the regulatory path: the FDA's 2024 clearance of over-the-counter CGMs and what it means for the category. A focused look at how a medical device is becoming a consumer health gadget and whether the science is keeping up.

#ContinuousGlucoseMonitor #CGM #Abbott #Dexcom #FreestyleLibre #DexcomG7 #Levels #NutriSense #Wearables #DigitalHealth #Wellness #HealthTech #FDA #GlucoseMonitoring #Business #Technology #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo

Lucas and Luna dig into an escalating regulatory war that most consumers don't even know exists. Fitbit's new sleep apnea detection feature got FDA clearance in March 2026, and Apple's atrial fibrillation algorithm now powers a multi-center clinical trial enrolling 15,000 patients. But behind the headlines, both companies are waging a quiet battle over something much bigger: who gets to own the FDA-cleared claim for 'passive health screening' on a wrist-worn device. Lucas walks through the specific filings, the timing, and the commercial stakes — including why Medicare reimbursement is the real prize. Luna brings up the tension between algorithmic transparency and proprietary hardware, and asks whether either company's data is actually good enough for a doctor to act on. The episode pulls back the curtain on a defensive land grab that will determine how your smartwatch talks to your doctor by 2028.

#Fitbit #Apple #Wearables #FDA #SleepApnea #AFib #MedTech #ClinicalTrial #HealthRegulation #Algorithm #Reimbursement #DigitalHealth #PassiveScreening #WristWorn #Business #Technology #FexingoBusiness #BusinessPodcast

Keep every episode free: buymeacoffee.com/fexingo